Lifecore Biomedical
LFCR
125 hedge funds and large institutions have $287M invested in Lifecore Biomedical in 2013 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 54 increasing their positions, 42 reducing their positions, and 13 closing their positions.
29% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 42
15% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 13
1% more funds holding
Funds holding: 124 → 125 (+1)
5% less capital invested
Capital invested by funds: $301M → $287M (-$14M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
98% less call options, than puts
Call options by funds: $10K | Put options by funds: $564K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCG
Opus Capital Group
Cincinnati,
Ohio
|
+$12.4M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$5.95M |
| 3 |
AI
Ariel Investments
Chicago,
Illinois
|
+$5.32M |
| 4 |
MOACM
Mutual of America Capital Management
New York
|
+$2.74M |
| 5 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
+$2.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$15.8M |
| 2 |
OSAM
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
-$4.32M |
| 3 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$2.52M |
| 4 |
WC
Wynnefield Capital
New York
|
-$2.3M |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$2.3M |
LFCR Hedge Fund Activity: Q3 2013 in Review
125 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q3 2013, worth a combined $287M — down 4.7% from $301M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LFCR positions and 13 closed out — a net gain of 2 holders — while 54 added to existing stakes and 42 trimmed.
The largest buyer was Opus Capital Group, adding an estimated $12.4M. The largest seller was Fidelity Investments, cutting an estimated $15.8M.
- 125 institutional investors held Lifecore Biomedical (LFCR) as of Q3 2013, up from 124 in Q2 2013.
- Funds reported $287M of Lifecore Biomedical stock for Q3 2013, down 4.7% quarter-over-quarter.
- 15 funds opened new Lifecore Biomedical positions in Q3 2013 and 13 closed out, a net change of +2 holders.
- The largest Lifecore Biomedical buyer in Q3 2013 was Opus Capital Group, an estimated $12.4M added.
- The largest Lifecore Biomedical seller in Q3 2013 was Fidelity Investments, an estimated $15.8M sold.
Based on aggregated 13F filings for Q3 2013.